SCHEMBL20129029

SCHEMBL20129029

Cn1c2ccncc2c2c(F)c(F)c(-c3ccc(OCCOCCOCCOCCOCCOCc4ccccc4)nc3)cc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TOP2A P11388 1/20 0.35
ELOVL1 Q9BW60 1/20 0.34
CYP11B1 P15538 2/20 0.34
CYP11B2 P19099 2/20 0.34
PDE10A Q9Y233 7/20 0.34
PDE4A P27815 6/20 0.34
PDE4B Q07343 6/20 0.34
PDE3B Q13370 6/20 0.34
PDE3A Q14432 4/20 0.34
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
RPS6KA3 P51812 1/20 0.33
FAAH O00519 1/20 0.33
SGMS1 Q86VZ5 1/20 0.33
SGMS2 Q8NHU3 1/20 0.33
GRIN1 Q05586 2/20 0.32
GRIN2B Q13224 2/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
GRM2 Q14416 1/20 0.32
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27097798 0.87 PTGES (0.35) TOP2AELOVL1MAOAMAOBRPS6KA3
SCHEMBL20120547 0.81 CHEK1 (0.40) ELOVL1CYP11B1CYP11B2PDE10ARPS6KA3
SCHEMBL20128974 0.77 ATM (0.40) ELOVL1MAOAMAOBGRM2ATM
SCHEMBL20128578 0.76 MAPT (0.43) TOP2APDE10AGRIN1GRIN2B
SCHEMBL20128573 0.75 ADORA3 (0.41) TOP2ARPS6KA3GRIN1GRIN2B
SCHEMBL20120335 0.75 BRD9 (0.48)
SCHEMBL20128562 0.74 TOP2A (0.46) TOP2ACYP11B1CYP11B2MAOA
SCHEMBL20129030 0.73 NR1H2 (0.36) RPS6KA3PTGDR2
SCHEMBL29547487 0.73 ELOVL1 (0.36) ELOVL1CYP11B1CYP11B2MAOAMAOB
SCHEMBL20120688 0.73 ELOVL1 (0.36) ELOVL1CYP11B1CYP11B2MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN TOP2A 2219/4885ELOVL1 3910/4885CYP11B1 4138/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 TOP2A 2681/4885ELOVL1 3813/4885CYP11B1 4183/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.